Mustang Bio, Inc. (NasdaqCM: MBIO)
Health Care · Biotechnology · US
$0.57
-1.62% today · -62.4% 1Y
Mustang Bio, Inc. (NasdaqCM: MBIO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $4.38M and employs 4 people.
Over the last twelve months the share price has lost 62.4%, trading between 0.52 and 1.85.
Tweenvest scores Mustang Bio, Inc. across four factors: quality 26/100. Its strongest factor is quality.
MBIO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $4.38M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.46
- Dividend yield
- —
- Beta (5Y)
- 2.05
- 52-week high
- $1.85
- 52-week low
- $0.52
- Avg volume (3M)
- —
- Shares outstanding
- 7.58M
- Employees
- 4
- Next earnings
- —
About Mustang Bio, Inc.
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
- ISIN
- US62818Q3020
- Founded
- 2015
- Listed since
- Aug 22, 2017
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $266.13 | +0.61% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.85 | +0.00% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $147.79 | +0.72% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $553.94 | +1.16% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $834.55 | +0.73% |
| argenx SEENXTBR: ARGX | $63.06B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $157.42 | +13.34% |
Figures last refreshed Aug 18, 2026.